Search

21 Jul 2023: Alan Fersht. Tumour suppressor p53 structure and drug discovery. Alan Fersht was a Natural Sciences undergraduate and Chemistry postgraduate at Gonville and Caius from 1962-68. ... Cancer is a disease of mutation, and the most commonly mutated protein by

20 May 2024: Alan Fersht - Tumour suppressor p53 structure and drug discovery.

{"id":61,"date":"2012-06-25T10:03:42","date_gmt":"2012-06-25T10:03:42","guid":{"rendered":"http://www2.mrc-lmb.cam.ac.uk/wordpress/?page_id=61"},"modified":"2024-05-20T14:39:16","modified_gmt":"2024-05-20T13:39:16","slug":"protein-and-nucleic-acid-ch

26 Jan 2021: Cancer is a disease of mutation, and the most commonly mutated protein by far is the tumour suppressor p53. ... Tumour Suppressor p53. Structural Biology and Drug Discovery. Alan Fersht. MRC Laboratory of Molecular Biology.

21 Jul 2023: Tumour suppressor p53 structure and drug discovery. LMB Division - Protein and Nucleic Acid Chemistry.

Alan rejoined the LMB in 2010, where he continued his work on protein folding, misfolding and disease, concentrating on the tumour suppressor p53 until the end of 2017. ... n. Cancer is a disease of mutation, and the most commonly mutated protein by far

can bind to and deactivate an enzyme that controls the stability of the p53 tumour suppressor protein. ... This deactivation allows p53 to be turned on, putting the brakes on cancer growth.

20 Oct 2017: can bind to and deactivate an enzyme that controls the stability of the p53 tumour suppressor protein. ... This deactivation allows p53 to be turned on, putting the brakes on cancer growth.

nAlan will continue to lead his research on the p53 tumour suppressor protein at the LMB with an MRC programme grant for the next five years.

n. Professor Sir Alan Fersht, FRS, from the PNAC Division of LMB, has been awarded an Advanced ERC Grant of u20ac1.5m for his project u201cTumour suppressor p53: structure, stability and ... 70% of human cancers have p53 directly inactivated by mutation.

{"id":18741,"date":"2020-08-04T17:10:07","date_gmt":"2020-08-04T16:10:07","guid":{"rendered":"https://www2.mrc-lmb.cam.ac.uk/?p=18741"},"modified":"2020-08-04T17:10:09","modified_gmt":"2020-08-04T16:10:09","slug":"alan-fersht-and-marta-zlatic-win-roy

24 Sep 2010: Alan will continue to lead his research on the p53 tumour suppressor protein at the LMB with an MRC programme grant for the next five years.

26 Nov 2010: Professor Sir Alan Fersht, FRS, from the PNAC Division of LMB, has been awarded an Advanced ERC Grant of 1.5m for his project “Tumour suppressor p53: structure, stability and novel ... Alan’s grant complements his MRC programme grant on the

4 Aug 2020: Alan’s most recent interest is in the tumour suppressor p53, with the aim to understand how mutations affect its function, so that novel anti-cancer drugs may be designed to